SARCOMEDUSA

Additionally, the company has an option on a no-alpha IL-2 mutein for cancer. SarcoMedUSA is working with Roswell Park Cancer Center in New York. There are final toxicology studies being completed and humanized mice studies. The drug has been used in the clinic whereby two (2) of twelve (12) patients with advanced cancer had partial remission... SarcoMedUSA is working with Generium who received agency approval in Russia for Tigerase, a DNase 1. Below is a link to the paper that covers their Phase 3 study. approval study compared with Pulmozyme. https://pubmed.ncbi.nlm.nih.gov/34941914/

Also known as: SarcoMedUSA INC.

Primary location: Houston United States